CN105412466A - Pharmaceutic preparation for treating endometrial impairment type hypomenorrhea - Google Patents
Pharmaceutic preparation for treating endometrial impairment type hypomenorrhea Download PDFInfo
- Publication number
- CN105412466A CN105412466A CN201610015670.XA CN201610015670A CN105412466A CN 105412466 A CN105412466 A CN 105412466A CN 201610015670 A CN201610015670 A CN 201610015670A CN 105412466 A CN105412466 A CN 105412466A
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- hypomenorrhea
- pharmaceutical preparation
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010021033 Hypomenorrhoea Diseases 0.000 title claims abstract description 36
- 208000037093 Menstruation Disturbances Diseases 0.000 title claims abstract description 36
- 230000002357 endometrial effect Effects 0.000 title claims abstract description 28
- 230000006735 deficit Effects 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 59
- 238000011282 treatment Methods 0.000 claims abstract description 48
- 210000000582 semen Anatomy 0.000 claims abstract description 29
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 28
- 241000522226 Campylotropis Species 0.000 claims description 27
- 241000756943 Codonopsis Species 0.000 claims description 26
- 241000207782 Convolvulaceae Species 0.000 claims description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 239000002775 capsule Substances 0.000 claims description 21
- 238000002481 ethanol extraction Methods 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 8
- 239000012567 medical material Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 6
- 230000001476 alcoholic effect Effects 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 5
- 239000000470 constituent Substances 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000013049 sediment Substances 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 238000005507 spraying Methods 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 239000008298 dragée Substances 0.000 claims description 2
- 239000002662 enteric coated tablet Substances 0.000 claims description 2
- 239000007941 film coated tablet Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 235000012907 honey Nutrition 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000011505 plaster Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- -1 sublimed preparation Substances 0.000 claims description 2
- 239000007940 sugar coated tablet Substances 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 52
- 210000004369 blood Anatomy 0.000 abstract description 52
- 210000003734 kidney Anatomy 0.000 abstract description 23
- 210000004185 liver Anatomy 0.000 abstract description 20
- 230000017531 blood circulation Effects 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 17
- 210000004291 uterus Anatomy 0.000 abstract description 14
- 230000002175 menstrual effect Effects 0.000 abstract description 6
- 241000615559 Codonopsis convolvulacea Species 0.000 abstract 1
- 244000018716 Impatiens biflora Species 0.000 abstract 1
- 235000015912 Impatiens biflora Nutrition 0.000 abstract 1
- 241000122904 Mucuna Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 235000005155 Tanacetum balsamita Nutrition 0.000 abstract 1
- 241000606278 Triplostegia Species 0.000 abstract 1
- 230000036299 sexual function Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 description 23
- 229940079593 drug Drugs 0.000 description 21
- 208000002193 Pain Diseases 0.000 description 19
- 230000036407 pain Effects 0.000 description 19
- 230000005906 menstruation Effects 0.000 description 16
- 239000000243 solution Substances 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 230000007812 deficiency Effects 0.000 description 12
- 239000000796 flavoring agent Substances 0.000 description 11
- 235000019634 flavors Nutrition 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 210000004696 endometrium Anatomy 0.000 description 10
- 201000000736 Amenorrhea Diseases 0.000 description 9
- 206010001928 Amenorrhoea Diseases 0.000 description 9
- 206010000210 abortion Diseases 0.000 description 9
- 231100000176 abortion Toxicity 0.000 description 9
- 231100000540 amenorrhea Toxicity 0.000 description 9
- 230000027758 ovulation cycle Effects 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 208000019255 Menstrual disease Diseases 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- 208000004998 Abdominal Pain Diseases 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 208000002173 dizziness Diseases 0.000 description 7
- 210000004914 menses Anatomy 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 6
- 238000004080 punching Methods 0.000 description 6
- 210000002435 tendon Anatomy 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 208000005171 Dysmenorrhea Diseases 0.000 description 5
- 206010013935 Dysmenorrhoea Diseases 0.000 description 5
- 206010027514 Metrorrhagia Diseases 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 208000009205 Tinnitus Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- 230000002040 relaxant effect Effects 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 231100000886 tinnitus Toxicity 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 208000007502 anemia Diseases 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 210000003127 knee Anatomy 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 206010000077 Abdominal mass Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 208000025747 Rheumatic disease Diseases 0.000 description 3
- 240000005498 Setaria italica Species 0.000 description 3
- 206010046788 Uterine haemorrhage Diseases 0.000 description 3
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 201000001881 impotence Diseases 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 235000002252 panizo Nutrition 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000000552 rheumatic effect Effects 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000002881 Colic Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010019909 Hernia Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010062575 Muscle contracture Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- 230000002254 contraceptive effect Effects 0.000 description 2
- 208000006111 contracture Diseases 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000003821 menstrual periods Effects 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 230000000624 ovulatory effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000037921 secondary disease Diseases 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 208000032984 Intraoperative Complications Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024419 Libido decreased Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010050031 Muscle strain Diseases 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010062104 Renal mass Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 201000006828 endometrial hyperplasia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 231100000545 luteal phase defect Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 235000019991 rice wine Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 238000011450 sequencing therapy Methods 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 208000008203 tachypnea Diseases 0.000 description 1
- 206010043089 tachypnoea Diseases 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
- A61K36/264—Aristolochia (Dutchman's pipe)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of traditional Chinese medicine, and relates to a pharmaceutic preparation for treating endometrial impairment type hypomenorrhea. The pharmaceutic preparation is prepared from semen cuscutae, prepared rehmannia roots, garden balsam stems, common peony roots, roots of lagerflower triplostegia, evergreen mucuna, herba aristolochiae, codonopsis convolvulacea, roots of hairy clovershrub, radix dipsaci and rhizoma cyperi elaborately based on a certain proportion. The pharmaceutic preparation can tonify kidney and liver, reinforce qi and nourish blood, promote blood circulation to remove blood stasis, clear and activate the channels and collaterals, powerfully improve sexual function of both sexes, nourish uterus, regulate thoroughfare and conception vessels, achieve both nourishing and dredging, make the best use of the circumstances and increase the amount of menstrual blood, and has a remarkable treatment effect.
Description
Technical field
The invention belongs to the field of Chinese medicines, relate to the medicine for the treatment of hypomenorrhea, particularly relate to a kind of pharmaceutical preparation for the treatment of endometrial impairment hypomenorrhea.
Background technology
Hypomenorrhea refers to that menstrual cycle is normal, and menstrual blood volume obviously reduces or the deficiency of time 2 days of passing through, even drop and clean person, ancient books has title " a small amount of menses and menstruating unsmoothly ", " few through water ", " very few through measuring " etc.Artificial abortion operation is unsuitable for continuing pregnant person after contraceptive failure or because of certain disease, or be prevention heredopathia and a kind of effective measures of congenital malformation person, and it causes hypomenorrhea comparatively common, is also the common difficult and complicated illness of gynecological clinic.Primary disease can cause infertile, miscarriage, even amenorrhea, and cause the series of problems such as mental maladjustment because of physiological change, clinical treatment is rather thorny, and effect is poor.
The hypomenorrhea that endometrial impairment causes is common with artificial abortion and uterine curettage, excessively scratch during artificial abortion and scrape uterine cavity, inhale that palace negative pressure is too high, overlong time, repeatedly to come in and go out cavity of uterus, these all can cause endometrial impairment, exposed or destroy inner membrance basal layer, cause endometrium poor, lack as, or cause Uterus wall involutory, form cicatrix, adhesion.Its reason is mainly because early pregnancy Uterus wall is softer, negative pressure inhale when scraping overexert, cross dark or cervix dilating coup injury cervical mucosal, neuron cell under it is impaired, the circular muscle contracture of isthmus uteri, impel cervical adhesion, and reflected by visceral nerve, make Endometrium be resting state to gonadal hormone poor response, make endometrium not generating period change, the clearing heat in the pericardium also can be like this, thus cause hypomenorrhea or amenorrhea.
Doctor trained in Western medicine is thought, female normal menstruation depends on the normal neuronal endocrine function of hypothalamic-pituitary-ovarian axis and mutually coordinates and normergic endometrium, therefore adopt artificial cycle therapy in treatment, because estrogen can promote the blood operation in uterus, the expansible uterine vascular of progestogen, uterus blood freight volume is increased, and both make endometrial hyperplasia at combined effect, thus repair impaired endometrium.
" abortion before the beautiful chi tire of gynecological " has cloud: " be know just product person, ripe as foxtail millet in fruit, its shell is from opening, and two without damaged.Abortion person, then still adopt and grind new foxtail millet, and its skin shell broken, damages its skin, then obtain in fact." Chinese medicine thinks, artificial abortion uses suction scraper tool directly to injure uterus, and channels damages, and also takes it by force as underdone foxtail millet, and inevitably will inevitably damage punching and appoint a uterus, the essence of Liver and kidney is impaired, asthenia of essence and blood, and a punching menoxenia due to insufficiency of CHONG meridian, causes through carrying out amount few; In addition surgical injury uterus, causes blood-stasis internal-depression, and passages through which vital energy circulates is not smooth, and retardance is appointed in punching, sends out as hypomenorrhea.
At present, often toxic and side effects is comparatively large for existing western medical treatment clinically, and easily recurs after drug withdrawal, and therapeutic effect is unsatisfactory, and people usually seek help from Chinese medicine.
Summary of the invention
Inventor overlaps theory and the clinical experience of oneself based on Chinese and western medicine two, modern Western medicine differential diagnosis of diseases and Chinese medical discrimination is combined, repeatedly practises, sums up, provide a kind of pharmaceutical preparation for the treatment of endometrial impairment hypomenorrhea, it has the kidney invigorating nourishing the liver, benefiting QI and nourishing blood, blood circulation promoting and blood stasis dispelling, the effect of dredge the meridian passage, the high benefit menses of energy, nourishes uterus, takes good care of punching and appoints, mend logical double executing, giving treatment in accordance with the tendency of pathological change, impels menses to increase, evident in efficacy.
The technical solution used in the present invention is as follows:
Treat a pharmaceutical preparation for endometrial impairment hypomenorrhea, it is that medicinal raw material is according to certain ratio elaborate by Semen Cuscutae, Radix Rehmanniae Preparata, Herba speranskiae tuberculatae, Radix Paeoniae Rubra, Radix Triplostegiae Grandiflorae, Radix Seu Caulis Mucunae Sempervirentis, Herba Aristolochiae, Radix Codonopsis Convolvulaceae, Radix Campylotropis hirtellae, Radix Dipsaci, Rhizoma Cyperi.
The present inventor tests through long-term, a large amount of screening prescriptions, be preferably as follows technical scheme further: a kind of pharmaceutical preparation for the treatment of endometrial impairment hypomenorrhea, it is made up of the medicinal raw material of following weight parts: Semen Cuscutae 15-30 part, Radix Rehmanniae Preparata 10-20 part, Herba speranskiae tuberculatae 12-24 part, Radix Paeoniae Rubra 8-16 part, Radix Triplostegiae Grandiflorae 20-40 part, Radix Seu Caulis Mucunae Sempervirentis 5-15 part, Herba Aristolochiae 15-30 part, Radix Codonopsis Convolvulaceae 10-20 part, Radix Campylotropis hirtellae 8-18 part, Radix Dipsaci 3-10 part, Rhizoma Cyperi 6-16 part.
Further preferably, treat a pharmaceutical preparation for endometrial impairment hypomenorrhea, it is made up of the medicinal raw material of following weight parts: Semen Cuscutae 18-24 part, Radix Rehmanniae Preparata 12-18 part, Herba speranskiae tuberculatae 16-22 part, Radix Paeoniae Rubra 9-15 part, Radix Triplostegiae Grandiflorae 25-30 part, Radix Seu Caulis Mucunae Sempervirentis 10-15 part, Herba Aristolochiae 18-26 part, Radix Codonopsis Convolvulaceae 13-18 part, Radix Campylotropis hirtellae 11-16 part, Radix Dipsaci 5-8 part, Rhizoma Cyperi 9-15 part.
Further preferably, treat a pharmaceutical preparation for endometrial impairment hypomenorrhea, it is made up of the medicinal raw material of following weight parts: Semen Cuscutae 20 parts, Radix Rehmanniae Preparata 16 parts, Herba speranskiae tuberculatae 18 parts, Radix Paeoniae Rubra 12 parts, Radix Triplostegiae Grandiflorae 25 parts, Radix Seu Caulis Mucunae Sempervirentis 10 parts, Herba Aristolochiae 24 parts, Radix Codonopsis Convolvulaceae 15 parts, Radix Campylotropis hirtellae 12 parts, Radix Dipsaci 5 parts, Rhizoma Cyperi 12 parts.
Fang Zhong: monarch drug: Semen Cuscutae, Radix Rehmanniae Preparata, Radix Rehmanniae Preparata: sweet tepor, nourishing YIN and supplementing blood, beneficial essence fills out marrow; The sweet temperature of Semen Cuscutae, nourishing the liver and kidney, solid protection kidney essense, has the effect that warming the spleen helps stomach concurrently, two medicine 5 nourishing the liver and kidney, life essence-filling, marrow-benefitting, can high benefit menses, nourishes uterus, makes benefit and not high, temperature and not dry.
Ministerial drug: the pungent temperature of Herba speranskiae tuberculatae, expelling wind and removing dampness, relaxing muscles and tendons to promote blood circulation, dissipating blood stasis for subsidence of swelling; Radix Paeoniae Rubra hardship is slightly cold, clearing away heat and cooling blood; Blood circulation promoting and blood stasis dispelling; Two medicine compatibilities, pungent temperature bitter cold use, blood circulation promoting and blood stasis dispelling, dissipating blood stasis for subsidence of swelling is ministerial drug.
Adjuvant drug: the sweet micro-hardship of Radix Triplostegiae Grandiflorae is put down, tonifying speen and tonifying kidney, promoting blood flow to regulate menstruation, Radix Codonopsis Convolvulaceae benefiting qi and nourishing blood, the lung moistening and production of body fluid promoting, and two medicine 5 blood yiqis, take good care of the five internal organs, principal drug assistance adjustment renal function, makes equilibrium between yin and yang coordinate.Radix Seu Caulis Mucunae Sempervirentis promoting blood flow to regulate menstruation, relaxing muscles and tendons of enriching blood; Herba Aristolochiae: promoting flow of QI and blood, inducing diuresis to remove edema; Radix Campylotropis hirtellae promoting blood flow to regulate menstruation, regulating QI to relieve pain, clearing away heat-damp and promoting diuresis; Radix Dipsaci invigorating the liver and kidney, bone and muscle strengthening, continuous injured; Four medicine 5 use, promoting flow of QI and blood, helps ministerial drug dissipating blood stasis to disappear stagnant, the passages through which vital energy circulates that maintenance is simultaneously impaired.
Adjuvant: Rhizoma Cyperi is gas medicine in blood, and micro-hardship can be fallen, micro-sweet energy and, QI and blood regulating.
All medicine 5 use, negative and positive are adjusted altogether, mend logical double executing, have the kidney invigorating nourishing the liver, blood circulation promoting and blood stasis dispelling, nourishing blood for regulating menstruation, the high benefit menses of energy, nourishes uterus, take good care of punching to appoint, for causing the cause of disease Be very effective such as the suffering from a deficiency of the kidney of artificial abortion endometrial impairment Hypomenorrhea, blood stasis, blood deficiency, treating both the principal and secondary aspects of a disease.
The pharmaceutical research present situation of the present invention's each medical material used is as described below.
Semen Cuscutae: [nature and flavor] are sweet, temperature.[return through] returns liver,kidney,spleen warp.[function cures mainly] nourishing the liver and kidney, controlling nocturnal emission with astringent drugs reducing urination, antiabortive, improving eyesight, antidiarrheal.For impotence and seminal emission, dripping urination, enuresis frequent micturition, soreness of the waist and knees, blurred vision tinnitus, vaginal bleeding due to deficiency of the kidney during pregnancy, frequent fetal movement, spleen is suffered from a deficiency of the kidney and is rushed down; Externally treating leucoderma.
Radix Rehmanniae Preparata: [nature and flavor] are sweet, tepor.[return through] returns liver, kidney channel.[function cures mainly] nourishing YIN and supplementing blood, beneficial essence fills out marrow.For the hepatic and renal YIN deficiency, soreness of the waist and knees, osteopyrexia and fever, night sweat is passed out semen, and interior-heat is quenched one's thirst, blood deficiency and yellow complexion, severe palpitation, menoxenia, and metrostaxis is dizzy, tinnitus, early whitening of beard and hair.[usage and dosage] 9 ~ 15g.
Herba speranskiae tuberculatae: [nature and flavor] are pungent; Warm in nature.[return through] lung; Liver Channel.[function cures mainly] expelling wind and removing dampness; Relaxing muscles and tendons to promote blood circulation; Dissipating blood stasis for subsidence of swelling; Removing toxic substances ophthalmalgia.Main air pain of dampness syndrome; Muscles and bones contracture; The disturbance of lower legs due to pathogenic cold and dampness; Lumbar strain; Paralysis; Amenorrhea; Eczema scrotum; Furuncle toxic swelling.
Radix Paeoniae Rubra: [nature and flavor] are bitter; Be slightly cold.[return through] liver; Spleen channel.[function cures mainly] clearing away heat and cooling blood; Blood circulation promoting and blood stasis dispelling.Main maculae caused by violent heat pathogen; Hematemesis and epistaxis; Discharging fresh blood stool; Conjunctival congestion and swelling pain; Carbuncle skin infection; Amenorrhea; Dysmenorrhea; Metrorrhagia and leukorrhagia stranguria with turbid discharge; The stagnant hypochondriac pain of the stasis of blood; Hernia abdominal mass is gathered; Injury from falling down.[usage and dosage] takes orally: decoct soup, 4-10g; Or enter ball, loose.
Radix Triplostegiae Grandiflorae: [nature and flavor] sweet, micro-hardship is flat.[function cures mainly] tonifying speen and tonifying kidney, promoting blood flow to regulate menstruation, only metrorrhagia, removing toxic substances.For lumbago due to renal deficiency, anemia, cough, seminal emission, sexual impotence, rheumatic arthritis, menoxenia, vicarious menstruation, metrorrhagia, leukorrhagia, infertility.External is stopped blooding." Yunnan Chinese herbal medicine ": regulating menstruation and activating blood, kidney tonifying.Control amenorrhea, menoxenia, lumbago due to renal deficiency, seminal emission, sexual impotence, infertility.
Radix Seu Caulis Mucunae Sempervirentis: [nature and flavor] are bitter; Micro-hardship; Warm in nature.[return through] liver; Stomach warp.[function cures mainly] promoting blood flow to regulate menstruation; To enrich blood relaxing muscles and tendons.Main have through uncomfortable; Dysmenorrhea; Amenorrhea; Puerperal blood deficiency; Anemia; Rheumatic arthralgia; Numb limbs and tense tendons; Traumatic injury.[usage and dosage] takes orally: decoct soup, 15-30g, or infusing drugs in wine.External: appropriate, smashes deposited." vegetation is side just ": blood circulation promoting and blood stasis dispelling, relaxing muscles and tendons, sharp joint.Control pain along the spinal column.
Herba Aristolochiae: [nature and flavor] are bitter; Temperature.[return through] liver; Spleen; Kidney channel.[function cures mainly] promoting flow of QI and blood; Inducing diuresis to remove edema; Removing toxic substances.Main stomachache; Colicky; Edema during pregnancy; Puerperal, vim and vigour were suffered from abdominal pain; Snake bite and insect sting." book on Chinese herbal medicine converges and says ": Herba Aristolochiae, gas is invigorated blood circulation, and controls the medicine of all pains also.The gas of the person, suitable then peaceful, the inverse then vexed work of pain.As Young " side of directing at " Herba Aristolochiae controls the brachialgia of expectorant note, gas stays colic, and abdominal mass is gathered, and renal mass is suffered from abdominal pain, and puerperal, vim and vigour were suffered from abdominal pain, and he is as edema during pregnancy, edema over the face tachypnea, man's wind labor, and chronic cough is not healed, and knows and controls it with this medicine, peace of invariably getting into bed.Gai Weiqi is good at popular vim and vigour therefore also.
Radix Codonopsis Convolvulaceae: [nature and flavor] sweet in the mouth; Micro-hardship; Slightly warm in nature.[function cures mainly] benefiting qi and nourishing blood; The lung moistening and production of body fluid promoting.Main anemia; Spontaneous perspiration; Milk is rare; Cough due to deficiency of the lung; Neurasthenia; Hernia.[usage and dosage] takes orally: decoct soup, 15-30g; Or fricassee clothes.
Radix Campylotropis hirtellae: [nature and flavor] are puckery, micro-hardship, tepor.[function cures mainly] promoting blood flow to regulate menstruation; Regulating QI to relieve pain; Clearing away heat-damp and promoting diuresis.Main menoxenia; Amenorrhea; Dysmenorrhea; Leucorrhea; Dysentery; Gastric abscess; Traumatic hemorrhage; Impetigo; Burn due to hot liquid or fire." Yunnan Chinese herbal medicine " carries: " regulating menstruation and activating blood, regulating QI to relieve pain.Control amenorrhea, dysmenorrhea, redly to collapse, leucorrhea, stomachache, digestive tract ulcer." modern medicine study confirmation, Radix Campylotropis hirtellae has method stasis of blood tissue regeneration promoting, promoting blood flow to regulate menstruation, hemostasis, the effect of removing toxic substances.
Radix Dipsaci: [nature and flavor] are bitter, pungent, tepor.[return through] returns liver, kidney channel.[function cures mainly] invigorating the liver and kidney, bone and muscle strengthening, continuous injured, only metrorrhagia.For soreness of the waist and knees, rheumatic arthralgia, metrorrhagia, vaginal bleeding during pregnancy, injury from falling down.Prepared RADIX DIPSACI with yellow rice wine is used for rheumatic arthralgia, injury from falling down.
Rhizoma Cyperi: [nature and flavor] pungent, micro-hardship, micro-sweet, flat.[return through] returns liver, spleen, tri-jiao channel.[function cures mainly] promoting QI circulation for relieving depression, menstruction regulating and pain relieving.For stagnation of QI due to depression of the liver, breast, the side of body, abdominal distention, dyspepsia, breast gastral cavity painful abdominal mass is vexed, and colic of cold type is suffered from abdominal pain, distending pain of the breast, menoxenia, amenorrhea dysmenorrhea." detailed outline ": " gas of Rhizoma Cyperi is flat and do not tremble with fear, fragrant and can alter, and how pungent its taste is can fall apart, and micro-hardship can be fallen, micro-sweet energy with.”
In order to express pharmaceutical preparation of the present invention better, pharmaceutical preparation of the present invention can be active component by Semen Cuscutae, Radix Rehmanniae Preparata, Herba speranskiae tuberculatae, Radix Paeoniae Rubra, Radix Triplostegiae Grandiflorae, Radix Seu Caulis Mucunae Sempervirentis, Herba Aristolochiae, Radix Codonopsis Convolvulaceae, Radix Campylotropis hirtellae, Radix Dipsaci, Rhizoma Cyperi or its water or its extractive with organic solvent, this composition is independent or mix with medicine acceptable carrier, makes according to galenic pharmacy routine techniques.
Described pharmaceutically acceptable carrier, as mannitol, sorbitol, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, cysteine hydrochloride, TGA, methionine, vitamin C, EDETATE SODIUM, Ethylenediaminetetraacetic Acid Calcium Salt, the alkali-metal carbonate of monovalence, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid, aminoacid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivative, cellulose and its derivates, alginate, gelatin, polyvinylpyrrolidone, glycerol, POLYSORBATE 80, agar, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, beta-schardinger dextrin-, phospholipid material, Kaolin, Pulvis Talci, calcium stearate, magnesium stearate etc.
Pharmaceutical preparation of the present invention is preferably made for peroral dosage form, as: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, honey pill agent, powder, sublimed preparation, solution or plaster etc.The peroral dosage form of pharmaceutical preparation further preferably of the present invention is tablet, capsule or granule, most preferably is capsule.
Present invention also offers the preparation method of pharmaceutical preparation described above, the present inventor finds under study for action, by optimized fabrication method, can when remaining valid medicine, remove impurity or the part without drug effect, reduce impurity to the interference of therapeutic effect, make this pharmaceutical preparation more effective, and reduce the consumption of medicine thus.
A kind of preparation method for the treatment of the pharmaceutical preparation of endometrial impairment hypomenorrhea provided by the invention, mainly comprises the following steps:
Get Herba speranskiae tuberculatae, Radix Paeoniae Rubra, Radix Seu Caulis Mucunae Sempervirentis, Herba Aristolochiae, add the alcoholic solution of medical material amount 4-8 times 50%, extract secondary, each 1.5-2.0 hour, filtered while hot, is concentrated into and obtains ethanol extraction concentrated solution without alcohol taste; Get Semen Cuscutae, Radix Rehmanniae Preparata, Radix Triplostegiae Grandiflorae, Radix Codonopsis Convolvulaceae, Radix Campylotropis hirtellae, Radix Dipsaci, Rhizoma Cyperi together with filtering residue after Herba speranskiae tuberculatae, Radix Paeoniae Rubra, Radix Seu Caulis Mucunae Sempervirentis, Herba Aristolochiae ethanol extraction, add 5-10 times of water soaking 3-4 hour, decoct extraction twice, each 1.5-2.0 hour (timing from during boiling); Filtered while hot, be concentrated into relative density 1.05-1.10 (60 DEG C record), adding ethanol makes alcohol content be 35%, leaves standstill after 24 hours, centrifugal 20 minutes (rotating speed is 3000r/min), discard lower sediment thing, obtain supernatant, be concentrated into relative density 1.05-1.10 (60 DEG C record) and mix with above-mentioned ethanol extraction concentrated solution afterwards, inlet temperature 140 ~ 150 DEG C, carry out spraying dry under leaving air temp 75 ~ 80 DEG C of conditions, obtain active constituents of medicine; This composition is independent or mix with medicine acceptable carrier, makes pharmaceutical preparation of the present invention according to galenic pharmacy routine techniques.
In a word, compared with prior art, the present invention has following beneficial effect:
Selected by invention medicine, medical material compatibility is suitable, meets Chinese medicine and pharmacy and modern medicine theory, and legislation comprehensively, medication is thoughtful, all medicine 5 use, and negative and positive are adjusted altogether, mend logical double executing, have the kidney invigorating nourishing the liver, blood circulation promoting and blood stasis dispelling, the merit of nourishing blood for regulating menstruation, the high benefit menses of energy, nourishes uterus, takes good care of punching and appoints, for causing artificial abortion endometrial impairment Hypomenorrhea Be very effective, treating both the principal and secondary aspects of a disease.
The present invention is based on dialectical theory, catch patient to suffer from a deficiency of the kidney, blood deficiency this, take into account the mark of blood stasis, negative and positive are also adjusted, reinforcement and elimination in combination, strengthening vital QI to eliminate pathogenic factors, side effect is less, and patient compliance is better, taking convenience, can effectively alleviate patient's burden and misery, the object for the treatment of both the principal and secondary aspects of a disease can be reached, and approved by extensive patients.
Detailed description of the invention
Further describe the present invention below by way of specific embodiment, the present invention is not limited only to following examples.Within the scope of the invention or not departing from content of the present invention, spirit and scope, the change carried out the present invention, combination or replacement, be apparent for a person skilled in the art, and be included within the scope of the present invention.
Embodiment 1 capsule
Prescription: Semen Cuscutae 20 parts, Radix Rehmanniae Preparata 16 parts, Herba speranskiae tuberculatae 18 parts, Radix Paeoniae Rubra 12 parts, Radix Triplostegiae Grandiflorae 25 parts, Radix Seu Caulis Mucunae Sempervirentis 10 parts, Herba Aristolochiae 24 parts, Radix Codonopsis Convolvulaceae 15 parts, Radix Campylotropis hirtellae 12 parts, Radix Dipsaci 5 parts, Rhizoma Cyperi 12 parts.
Preparation method:
Get Herba speranskiae tuberculatae, Radix Paeoniae Rubra, Radix Seu Caulis Mucunae Sempervirentis, Herba Aristolochiae, add the alcoholic solution of medical material amount 4-8 times 50%, extract secondary, each 1.5-2.0 hour, filtered while hot, is concentrated into and obtains ethanol extraction concentrated solution without alcohol taste; Get Semen Cuscutae, Radix Rehmanniae Preparata, Radix Triplostegiae Grandiflorae, Radix Codonopsis Convolvulaceae, Radix Campylotropis hirtellae, Radix Dipsaci, Rhizoma Cyperi together with filtering residue after Herba speranskiae tuberculatae, Radix Paeoniae Rubra, Radix Seu Caulis Mucunae Sempervirentis, Herba Aristolochiae ethanol extraction, add 5-10 times of water soaking 3-4 hour, decoct extraction twice, each 1.5-2.0 hour (timing from during boiling); Filtered while hot, be concentrated into relative density 1.05-1.10 (60 DEG C record), adding ethanol makes alcohol content be 35%, leaves standstill after 24 hours, centrifugal 20 minutes (rotating speed is 3000r/min), discard lower sediment thing, obtain supernatant, be concentrated into relative density 1.05-1.10 (60 DEG C record) and mix with above-mentioned ethanol extraction concentrated solution afterwards, inlet temperature 140 ~ 150 DEG C, carry out spraying dry under leaving air temp 75 ~ 80 DEG C of conditions, obtain active constituents of medicine; This capsule is made according to galenic pharmacy routine techniques.
Capsule every prepared by the present embodiment is containing crude drug 1.7g.
Embodiment 2 capsule
Prescription: Semen Cuscutae 18 parts, Radix Rehmanniae Preparata 15 parts, Herba speranskiae tuberculatae 20 parts, Radix Paeoniae Rubra 15 parts, Radix Triplostegiae Grandiflorae 30 parts, Radix Seu Caulis Mucunae Sempervirentis 12 parts, Herba Aristolochiae 18 parts, Radix Codonopsis Convolvulaceae 15 parts, Radix Campylotropis hirtellae 12 parts, Radix Dipsaci 6 parts, Rhizoma Cyperi 10 parts.
Preparation method: with reference to embodiment 1.
Embodiment 3 capsule
Prescription: Semen Cuscutae 22 parts, Radix Rehmanniae Preparata 16 parts, Herba speranskiae tuberculatae 20 parts, Radix Paeoniae Rubra 10 parts, Radix Triplostegiae Grandiflorae 27 parts, Radix Seu Caulis Mucunae Sempervirentis 15 parts, Herba Aristolochiae 20 parts, Radix Codonopsis Convolvulaceae 15 parts, Radix Campylotropis hirtellae 10 parts, Radix Dipsaci 5 parts, Rhizoma Cyperi 8 parts.
Preparation method: with reference to embodiment 1.
Embodiment 4 capsule
Prescription: Semen Cuscutae 24 parts, Radix Rehmanniae Preparata 18 parts, Herba speranskiae tuberculatae 22 parts, Radix Paeoniae Rubra 15 parts, Radix Triplostegiae Grandiflorae 28 parts, Radix Seu Caulis Mucunae Sempervirentis 10 parts, Herba Aristolochiae 30 parts, Radix Codonopsis Convolvulaceae 20 parts, Radix Campylotropis hirtellae 15 parts, Radix Dipsaci 8 parts, Rhizoma Cyperi 13 parts.
Preparation method: with reference to embodiment 1.
Embodiment 5 capsule
Prescription: Semen Cuscutae 18 parts, Radix Rehmanniae Preparata 10 parts, Herba speranskiae tuberculatae 15 parts, Radix Paeoniae Rubra 10 parts, Radix Triplostegiae Grandiflorae 20 parts, Radix Seu Caulis Mucunae Sempervirentis 12 parts, Herba Aristolochiae 20 parts, Radix Codonopsis Convolvulaceae 12 parts, Radix Campylotropis hirtellae 8 parts, Radix Dipsaci 8 parts, Rhizoma Cyperi 10 parts.
Preparation method: with reference to embodiment 1.
Embodiment 6 capsule
Prescription: Semen Cuscutae 25 parts, Radix Rehmanniae Preparata 15 parts, Herba speranskiae tuberculatae 20 parts, Radix Paeoniae Rubra 15 parts, Radix Triplostegiae Grandiflorae 40 parts, Radix Seu Caulis Mucunae Sempervirentis 10 parts, Herba Aristolochiae 20 parts, Radix Codonopsis Convolvulaceae 10 parts, Radix Campylotropis hirtellae 15 parts, Radix Dipsaci 7 parts, Rhizoma Cyperi 15 parts.
Preparation method: with reference to embodiment 1.
Embodiment 7 tablet
Prescription: Semen Cuscutae 15 parts, Radix Rehmanniae Preparata 12 parts, Herba speranskiae tuberculatae 16 parts, Radix Paeoniae Rubra 10 parts, Radix Triplostegiae Grandiflorae 20 parts, Radix Seu Caulis Mucunae Sempervirentis 15 parts, Herba Aristolochiae 15 parts, Radix Codonopsis Convolvulaceae 20 parts, Radix Campylotropis hirtellae 10 parts, Radix Dipsaci 7 parts, Rhizoma Cyperi 10 parts.
Preparation method: get Herba speranskiae tuberculatae, Radix Paeoniae Rubra, Radix Seu Caulis Mucunae Sempervirentis, Herba Aristolochiae, adds the alcoholic solution of medical material amount 4-8 times 50%, and extract secondary, each 1.5-2.0 hour, filtered while hot, is concentrated into and obtains ethanol extraction concentrated solution without alcohol taste; Get Semen Cuscutae, Radix Rehmanniae Preparata, Radix Triplostegiae Grandiflorae, Radix Codonopsis Convolvulaceae, Radix Campylotropis hirtellae, Radix Dipsaci, Rhizoma Cyperi together with filtering residue after Herba speranskiae tuberculatae, Radix Paeoniae Rubra, Radix Seu Caulis Mucunae Sempervirentis, Herba Aristolochiae ethanol extraction, add 5-10 times of water soaking 3-4 hour, decoct extraction twice, each 1.5-2.0 hour (timing from during boiling); Filtered while hot, be concentrated into relative density 1.05-1.10 (60 DEG C record), adding ethanol makes alcohol content be 35%, leaves standstill after 24 hours, centrifugal 20 minutes (rotating speed is 3000r/min), discard lower sediment thing, obtain supernatant, be concentrated into relative density 1.05-1.10 (60 DEG C record) and mix with above-mentioned ethanol extraction concentrated solution afterwards, inlet temperature 140 ~ 150 DEG C, carry out spraying dry under leaving air temp 75 ~ 80 DEG C of conditions, obtain active constituents of medicine; This tablet is made according to galenic pharmacy routine techniques.
Tablet prepared by the present embodiment, every sheet 0.3g, containing crude drug 1.7g
Embodiment 8 tablet
Prescription: Semen Cuscutae 20 parts, Radix Rehmanniae Preparata 16 parts, Herba speranskiae tuberculatae 18 parts, Radix Paeoniae Rubra 12 parts, Radix Triplostegiae Grandiflorae 25 parts, Radix Seu Caulis Mucunae Sempervirentis 10 parts, Herba Aristolochiae 24 parts, Radix Codonopsis Convolvulaceae 5 parts, Radix Campylotropis hirtellae 12 parts, Radix Dipsaci 5 parts, Rhizoma Cyperi 12 parts.
Preparation method: with reference to embodiment 7.
Embodiment 9 granule
Prescription: Semen Cuscutae 20 parts, Radix Rehmanniae Preparata 16 parts, Herba speranskiae tuberculatae 18 parts, Radix Paeoniae Rubra 12 parts, Radix Triplostegiae Grandiflorae 25 parts, Radix Seu Caulis Mucunae Sempervirentis 10 parts, Herba Aristolochiae 24 parts, Radix Codonopsis Convolvulaceae 5 parts, Radix Campylotropis hirtellae 12 parts, Radix Dipsaci 5 parts, Rhizoma Cyperi 12 parts.
Preparation method:
Get Herba speranskiae tuberculatae, Radix Paeoniae Rubra, Radix Seu Caulis Mucunae Sempervirentis, Herba Aristolochiae, add the alcoholic solution of medical material amount 4-8 times 50%, extract secondary, each 1.5-2.0 hour, filtered while hot, is concentrated into and obtains ethanol extraction concentrated solution without alcohol taste; Get Semen Cuscutae, Radix Rehmanniae Preparata, Radix Triplostegiae Grandiflorae, Radix Codonopsis Convolvulaceae, Radix Campylotropis hirtellae, Radix Dipsaci, Rhizoma Cyperi together with filtering residue after Herba speranskiae tuberculatae, Radix Paeoniae Rubra, Radix Seu Caulis Mucunae Sempervirentis, Herba Aristolochiae ethanol extraction, add 5-10 times of water soaking 3-4 hour, decoct extraction twice, each 1.5-2.0 hour (timing from during boiling); Filtered while hot, be concentrated into relative density 1.05-1.10 (60 DEG C record), adding ethanol makes alcohol content be 35%, leaves standstill after 24 hours, centrifugal 20 minutes (rotating speed is 3000r/min), discard lower sediment thing, obtain supernatant, be concentrated into relative density 1.05-1.10 (60 DEG C record) and mix with above-mentioned ethanol extraction concentrated solution afterwards, inlet temperature 140 ~ 150 DEG C, carry out spraying dry under leaving air temp 75 ~ 80 DEG C of conditions, obtain active constituents of medicine; This granule is made according to galenic pharmacy routine techniques.
Embodiment 10 granule
Prescription: Semen Cuscutae 18 parts, Radix Rehmanniae Preparata 10 parts, Herba speranskiae tuberculatae 15 parts, Radix Paeoniae Rubra 10 parts, Radix Triplostegiae Grandiflorae 20 parts, Radix Seu Caulis Mucunae Sempervirentis 12 parts, Herba Aristolochiae 20 parts, Radix Codonopsis Convolvulaceae 12 parts, Radix Campylotropis hirtellae 8 parts, Radix Dipsaci 8 parts, Rhizoma Cyperi 10 parts.
Preparation method: with reference to embodiment 9.
Embodiment 11 animal experiment embodiment result
Acute toxicity testing result shows: by capsule 's content Cmax of the present invention, maximum volume gastric infusion, successive administration 3 times in 24h, every minor tick 4h, and accumulation medicine total amount reaches 34g crude drug/kg, is equivalent to more than 300 times of clinical plan consumption.After administration in 7d, mice activity, feed, excretion are all normal, well-grown, and hair color light, its average body weight average increases with the prolongation of test period.8d place post mortem every the mice perusal heart, liver, spleen, lung, kidney, brain, thymus, adrenal gland, stomach, intestinal etc. all do not find color and paramophia.Show that capsule of the present invention is without acute toxic reaction.
Long term toxicity test result shows: capsule 's content of the present invention is divided into basic, normal, high dosage to be respectively 3.4,6.8,13.6g crude drug/kg/d, gastric infusion is after 12 weeks, capsule 's content of the present invention is on the general status of animal, hematological indices, blood parameters all without significantly impact, and Systematic anatomy, organ coefficient and histopathological examination be no abnormal pathological change also.Drug withdrawal also has no obvious change in 2 weeks.Compound Chinese caterpillar fungus blood nourishing granule, in long term toxicity test, does not find overt toxicity reaction and delayed toxicity reaction.Visible, capsule non-toxic reaction of the present invention, long-term prescription is safe and reliable.
Embodiment 12 clinical observation experiment
1 data and method
1.1 physical data: observe in January, 2014 to 2014 year December and go to a doctor and be diagnosed as patient 128 example of endometrial impairment hypomenorrhea in my institute's Out-patient Clinic of Department of Gynecology, adopt and be divided into observation group and matched group to observe at random, often organize 64 routine.Observation group's max age 37 years old, minimal ages 18 years old, 27.7 years old mean age, the course of disease is the longest 6.5 years, the shortest 6 months, average 2.25, ovulatory inner film thickness (4.22 ± 1.27) mm.Matched group max age 39 years old, minimal ages 19 years old, average 27.3 years old; The course of disease is the longest 6.5 years, the shortest 7 months, average 2.06 years; Ovulatory inner film thickness (4.34 ± 1.31) mm, two groups of physical data compare no difference of science of statistics (P > 0.05), have comparability.
1.2 diagnostic criterias: the diagnostic criteria of writing the hypomenorrhea of " guideline of clinical investigations of new Chinese medicine treatment menoxenia " of " Gynecology of Chinese Medicine " and Ministry of Health of the People's Republic of China promulgation in 2002 according to Zhang Yuzhen etc.
Hypomenorrhea: hypomenorrhea refers to that menstrual cycle is normal, and menstrual blood loss comparatively constant obviously reduces, and even drop is namely clean, or through line time less than 2 days, through the menopathy that amount is also few.
Tcm diagnosis: primary symptom: few through row amount, color is dull, or has clot, soreness of the waist and knees;
Secondary disease: lower abdominal distention pain, clot discharges then pain relief; Back twinge, tenderness; Dizziness and tinnitus;
Tongue arteries and veins: light red tongue is purple, or has ecchymosis, petechia, thin fur, thready and hesitant pulse; Above primary symptom must possess, and at least accompanies a wherein time disease, in conjunction with tongue arteries and veins and diagnosable.
1.3 inclusive criterias: meet Disease Diagnosis Standard; There is artificial abortion medical history, Hypomenorrhea more than 3 months medical histories; B ultrasonic Monitoring Ovulation day endometrium thickness is less than 8mm; Basal body temperature (BBT) two-phase.
1.4 exclusion standards: have cryptorrhea, luteal phase defect, uterine cavity organic disease person; There are the Chronic consumptions persons such as hyperthyroidism, tuberculosis, severe anemia; There is oral hormone in 3 months, use contraceptive person; Untoward reaction person is there is in drug administration process; Not by regulation medication, cannot judge that curative effect or data are not congruent and affect the treatment or statistical disposition person.
1.5 Therapeutic Method:
Observation group: the capsule that menstruation brings into use the embodiment of the present invention 1 to prepare on the 5th day, every day twice, each 2-4 grain, takes and withdraws to during menstrual onset, is a course for the treatment of, takes 3 months continuously with 3 months.
Matched group: use Western medicine capable artificial cycle estrogen and progestogen sequential therapy, from menstruation the 5th day, the oral progynova 1mg of patient, 1 time/d, serve on 21d; Started from the 15th day, add with Progesterone soft gelatin capsule 100mg, 2 times/d, take to the 21st day and progynova drug withdrawal simultaneously.Continuous treatment 3 menstrual cycle.
1.6 treatment fore-and-aft observing indexs:
1.6.1 the change of menstruation--menstrual blood volume color, matter, passes through the time, menstrual cycle.
1.6.2 tcm symptom scoring: cardinal symptom standards of grading reference " tcm clinical practice Illnesses Diagnoses criterion of therapeutical effect ", primary symptom: Hypomenorrhea, dark through color, thin menses, lumbosacral aching pain, by nothing, slight, moderate, severe, counts 0,2,4,6 point respectively; Secondary disease: dizziness, tinnitus or deafness, hyposexuality, by nothing, slight, moderate, severe 0,1,2,3 point respectively.Extent of disease severity method is as follows: nothing: menstruation recovery is normal, and through amount >=20mL, color is red, continues 3d, does not have other symptoms; Slight: menstrual blood volume is comparatively front to be reduced, and color is dark, occasionally has lumbosacral aching pain, dizziness and blurred vision; Moderate: through amount minimizing more than 1/3, color is dark, and matter is thin, within continuing 2d, lumbosacral aching pain recurrent exerbation, dizzy, dim eyesight often occurs; Severe: namely clean through amount drop, lumbosacral aching pain continues outbreak, and dizzy, dim eyesight recurrent exerbation, not easily alleviates.
1.6.3 Transvaginal Ultrasound inspection at the end of the endometrium thickness evaluation index moon premenstrual (onset of ovulation) and the course for the treatment of: intrauterine thickness 8 ~ 14mm is normal.
1.6.4 the observation of adverse effect during medication: with or without occurring untoward reaction and record during observing medication, as gastrointestinal upset, anaphylaxis, vaginal bleeding time prolongation etc.As the person that occurs serious adverse reaction, discontinue medication immediately, exit this research.
1.7 statistical methods: adopt SPSS16.0 statistical software to calculate.Each numerical value with
represent, measurement data adopts t inspection, and enumeration data adopts χ
2inspection, with P < 0.05 for difference has statistical significance.
2 results
2.1 criterions of therapeutical effect: according to " guideline of clinical investigations of new Chinese medicine treatment menoxenia ", draft following criterion of therapeutical effect: recovery from illness: treat rear menstrual cycle, recover normal through amount, other transference cures, drug withdrawal 3 non-recidivists of menstrual cycle; Effective: menstrual blood volume increases by 1/3, and other transference cures alleviate, and drug withdrawal 3 menstrual cycle are without recidivist; Effective: treat rear menstrual cycle, through amount, comparatively treat front improvement menstrual period, other symptoms alleviate before comparatively treating; Invalid: treatment after menstrual cycle, through amount and menstrual period without improvement.
2.2 observation of curative effect
2.2.1 two groups of patient's comparitive study: after above-mentioned 128 routine patient treatments, observation group's recovery from illness 22 example, effective 29 examples, effective 12 examples, invalid 1 example, obvious effective rate 79.69%, total effective rate 98.44%; Matched group recovery from illness 13 example, effective 18 examples, effective 20 examples, invalid 13 examples, obvious effective rate 48.44%, total effective rate 79.69%, observation group compares with matched group obvious effective rate, total effective rate, and difference has statistical significance (P < 0.05), and observation group's effect is more excellent.In table 1.
Table 1 liang group patient's comparitive study (example)
Note: compare with matched group, * P < 0.05.
2.2.2 two groups of symptom integral compare: after treatment, two groups of symptom integral are all than obviously less before treatment, statistical significance (P < 0.01) is had with comparing difference before treatment, compare between two groups after treatment, difference has statistical significance (P < 0.05), and observation group's symptom integral reduces more obvious.In table 2.
Two groups, front and back symptom integral for the treatment of table 2 compares (
point)
Note: compare with before treatment, * P < 0.05, * * P < 0.01, compares with matched group after treatment,
#p < 0.05.
2.2.3 before and after two groups of treatments, endometrium thickness compares: after treatment, two groups of patient uterine's inner film thickness more all obviously increase than before treatment, statistical significance (P < 0.01) is had with comparing difference before treatment, compare between two groups after treatment, difference has statistical significance (P < 0.05), and observation group's effect is more obvious.In table 2.
A table 3 liang group treatment front and back endometrium thickness compares (
mm)
Note: compare with before treatment, * P < 0.05, * * P < 0.01, compares with matched group after treatment,
#p < 0.05.
2.2.4 the observation of adverse effect during medication: have 1 routine patient to occur slight gastrointestinal reaction during matched group patient medication.22 routine patients are had to occur slight gastrointestinal reaction during matched group patient medication, as Nausea and vomiting, upper abdomen dull pain; Have 4 routine patients to occur irregular colporrhagia, observation group compares with matched group, and difference has statistical significance, and observation group's less adverse effect, patient compliance is better.
In a word: the routine patient of observation group 64, after the embodiment of the present invention 1 treatment by Chinese herbs, total effective rate is up to 98.44%%, and average endometrium thickness can reach (7.57 ± 1.02) mm, and can obviously improve the symptoms such as Hypomenorrhea, lumbosacral aching pain, dizziness, tinnitus.Patient reflects that Western medicine side effect is large, and disease relapse after drug withdrawal, treatment by Chinese herbs can maintain the curative effect of more than 1 ~ 2 year after 1 course for the treatment of.
Pharmaceutical preparation of the present invention is for the patient of endometrial impairment hypomenorrhea, therapeutic effect is obvious, untoward reaction is few, supposition may have entirety with Chinese medicine and regulate and control, multisystem, too many levels, the feature of Mutiple Targets, controlled by integral syndrome differentiation opinion, obviously can improve the clinical symptoms of patient, may with adjustment hypothalamic-pituitary-ovarian axis, improve ovary to the reactivity of FSH, improve Ovary reserve and promote the blood circulation of ovary local, improve ovary blood to supply, promote endometrial growth, repair, simultaneously also may be relevant with the endometrial endometrial receptivity of raising.
Claims (10)
1. treat the pharmaceutical preparation of endometrial impairment hypomenorrhea for one kind, it is characterized in that by Semen Cuscutae, Radix Rehmanniae Preparata, Herba speranskiae tuberculatae, Radix Paeoniae Rubra, Radix Triplostegiae Grandiflorae, Radix Seu Caulis Mucunae Sempervirentis, Herba Aristolochiae, Radix Codonopsis Convolvulaceae, Radix Campylotropis hirtellae, Radix Dipsaci, Rhizoma Cyperi be that medicinal raw material is made, the weight of each medicinal raw material is as follows: Semen Cuscutae 15-30 part, Radix Rehmanniae Preparata 10-20 part, Herba speranskiae tuberculatae 12-24 part, Radix Paeoniae Rubra 8-16 part, Radix Triplostegiae Grandiflorae 20-40 part, Radix Seu Caulis Mucunae Sempervirentis 5-15 part, Herba Aristolochiae 15-30 part, Radix Codonopsis Convolvulaceae 10-20 part, Radix Campylotropis hirtellae 8-18 part, Radix Dipsaci 3-10 part, Rhizoma Cyperi 6-16 part.
2. the pharmaceutical preparation for the treatment of endometrial impairment hypomenorrhea as claimed in claim 1, is characterized in that being made up of the medicinal raw material of following weight parts proportioning: Semen Cuscutae 18-24 part, Radix Rehmanniae Preparata 12-18 part, Herba speranskiae tuberculatae 16-22 part, Radix Paeoniae Rubra 9-15 part, Radix Triplostegiae Grandiflorae 25-30 part, Radix Seu Caulis Mucunae Sempervirentis 10-15 part, Herba Aristolochiae 18-26 part, Radix Codonopsis Convolvulaceae 13-18 part, Radix Campylotropis hirtellae 11-16 part, Radix Dipsaci 5-8 part, Rhizoma Cyperi 9-15 part.
3. the pharmaceutical preparation for the treatment of endometrial impairment hypomenorrhea as claimed in claim 2, is characterized in that being made up of the medicinal raw material of following weight parts proportioning: Semen Cuscutae 20 parts, Radix Rehmanniae Preparata 16 parts, Herba speranskiae tuberculatae 18 parts, Radix Paeoniae Rubra 12 parts, Radix Triplostegiae Grandiflorae 25 parts, Radix Seu Caulis Mucunae Sempervirentis 10 parts, Herba Aristolochiae 24 parts, Radix Codonopsis Convolvulaceae 15 parts, Radix Campylotropis hirtellae 12 parts, Radix Dipsaci 5 parts, Rhizoma Cyperi 12 parts.
4. the pharmaceutical preparation of the treatment endometrial impairment hypomenorrhea as described in claim 1-3, is characterized in that described pharmaceutical preparation is preferably made for peroral dosage form.
5. the pharmaceutical preparation for the treatment of endometrial impairment hypomenorrhea as claimed in claim 4, is characterized in that peroral dosage form is tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, sucks agent, granule, electuary, honey pill agent, powder, sublimed preparation, solution or plaster etc.
6. the pharmaceutical preparation for the treatment of endometrial impairment hypomenorrhea as claimed in claim 5, is characterized in that peroral dosage form is tablet, capsule or granule; Most preferably be capsule.
7. the pharmaceutical preparation for the treatment of endometrial impairment hypomenorrhea as claimed in claim 6, is characterized in that peroral dosage form most preferably is capsule.
8. the pharmaceutical preparation of the treatment endometrial impairment hypomenorrhea as described in claim 1-3, is characterized in that preparation method comprises the following steps:
Get Herba speranskiae tuberculatae, Radix Paeoniae Rubra, Radix Seu Caulis Mucunae Sempervirentis, Herba Aristolochiae, add the alcoholic solution of medical material amount 4-8 times 50%, extract secondary, each 1.5-2.0 hour, filtered while hot, is concentrated into and obtains ethanol extraction concentrated solution without alcohol taste; Get Semen Cuscutae, Radix Rehmanniae Preparata, Radix Triplostegiae Grandiflorae, Radix Codonopsis Convolvulaceae, Radix Campylotropis hirtellae, Radix Dipsaci, Rhizoma Cyperi together with filtering residue after Herba speranskiae tuberculatae, Radix Paeoniae Rubra, Radix Seu Caulis Mucunae Sempervirentis, Herba Aristolochiae ethanol extraction, add 5-10 times of water soaking 3-4 hour, decoct extraction twice, each 1.5-2.0 hour (timing from during boiling); Filtered while hot, be concentrated into relative density 1.05-1.10 (60 DEG C record), adding ethanol makes alcohol content be 35%, leaves standstill after 24 hours, centrifugal 20 minutes (rotating speed is 3000r/min), discard lower sediment thing, obtain supernatant, be concentrated into relative density 1.05-1.10 (60 DEG C record) and mix with above-mentioned ethanol extraction concentrated solution afterwards, inlet temperature 140 ~ 150 DEG C, carry out spraying dry under leaving air temp 75 ~ 80 DEG C of conditions, obtain active constituents of medicine; This composition is independent or mix with medicine acceptable carrier, makes pharmaceutical preparation of the present invention according to galenic pharmacy routine techniques.
9. the purposes of the arbitrary described pharmaceutical preparation of claim 1-3 in the medicine of preparation treatment endometrial impairment hypomenorrhea.
10. the purposes of the arbitrary described pharmaceutical preparation of claim 1-3 in the medicine of preparation treatment hypomenorrhea.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610015670.XA CN105412466A (en) | 2016-01-11 | 2016-01-11 | Pharmaceutic preparation for treating endometrial impairment type hypomenorrhea |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610015670.XA CN105412466A (en) | 2016-01-11 | 2016-01-11 | Pharmaceutic preparation for treating endometrial impairment type hypomenorrhea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105412466A true CN105412466A (en) | 2016-03-23 |
Family
ID=55491313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610015670.XA Withdrawn CN105412466A (en) | 2016-01-11 | 2016-01-11 | Pharmaceutic preparation for treating endometrial impairment type hypomenorrhea |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105412466A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102961644A (en) * | 2012-11-13 | 2013-03-13 | 陈维爱 | Traditional Chinese medicine composition for treating hypomenorrhea |
| CN104107318A (en) * | 2014-03-08 | 2014-10-22 | 毕玉珍 | Traditional Chinese medicinal composition for treating blood stasis stagnation type irregular menstruation |
-
2016
- 2016-01-11 CN CN201610015670.XA patent/CN105412466A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102961644A (en) * | 2012-11-13 | 2013-03-13 | 陈维爱 | Traditional Chinese medicine composition for treating hypomenorrhea |
| CN104107318A (en) * | 2014-03-08 | 2014-10-22 | 毕玉珍 | Traditional Chinese medicinal composition for treating blood stasis stagnation type irregular menstruation |
Non-Patent Citations (1)
| Title |
|---|
| 浙江省中医院编著: "《实用中医妇科手册》", 30 November 1996, 浙江科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104587439A (en) | Traditional Chinese medicine preparation for treating yang-deficiency internal-cold type dysmenorrhea and preparation method thereof | |
| CN104784643A (en) | Medicine for treating hysteromyoma, ovarian cyst and endometriosis | |
| CN103735721B (en) | A kind of Chinese medicine treating pink-eye | |
| CN103251886A (en) | Chinese medicine for treating postpartum lochiorrhea and preparation method thereof | |
| CN101417087B (en) | Medicine for treating gynecology postpartum disease and preparation method thereof | |
| CN103830657A (en) | Medicine for treating chronic cholecystitis | |
| CN100546617C (en) | A kind of Chinese medicine preparation for the treatment of oviduct obstructive sterility | |
| CN103550713B (en) | One treats hypertensive Chinese medicine | |
| CN105641445A (en) | Medicine composition for treating pubertal polycystic ovary syndrome and preparation method | |
| CN105521473A (en) | Poliomyelitis sequela treatment medicine and preparation method thereof | |
| CN105412466A (en) | Pharmaceutic preparation for treating endometrial impairment type hypomenorrhea | |
| CN102988883B (en) | Medicament for treating pneumonia and preparation method of medicament | |
| CN105288372A (en) | Pharmaceutical preparation for curing primary dysmenorrhea accompanied by acne | |
| CN105726868A (en) | Pharmaceutical preparation for treating first-trimester threatened abortion with anticardiolipin antibody positive | |
| CN105395768A (en) | Pharmaceutical composition for treating qi-blood deficiency type hypomenorrhea | |
| CN105597020A (en) | Pharmaceutical composition for treating polycystic ovarian syndrome combined with mammary gland hyperplasia | |
| CN104587376A (en) | Drug for treating qi stagnation and blood stasis-type thoracic obstruction and preparation method of drug oral liquid | |
| CN101181471B (en) | Medicament for curing pelvic inflammatory disease and preparation method thereof | |
| CN105497423A (en) | Pharmaceutical composition for hypomenorrhea caused by contraceptives | |
| CN105596631A (en) | Pharmaceutical preparation for treating hypomenorrhea caused by contraceptives | |
| CN105362963A (en) | Pharmaceutical preparation for treating hypomenorrhea of congealing cold and blood stasis | |
| CN105456942A (en) | Medicine preparation for treating hypomenorrhea caused by qi stagnation and blood stasis | |
| CN105362695A (en) | Medicinal preparation for treating hypomenorrhea with acne and preparation method of medicinal preparation | |
| CN105535348A (en) | Medicine composition for treating hypomenorrhea caused by contraceptive and preparation method thereof | |
| CN105362698A (en) | Medicine preparation for treating scanty menstruation after artificial abortion operation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160323 |
|
| WW01 | Invention patent application withdrawn after publication |